Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  McKesson Corporation    MCK

MCKESSON CORPORATION

(MCK)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/26/2020 06/29/2020 06/30/2020 07/01/2020 07/02/2020 Date
148.21(c) 151.77(c) 153.42(c) 150.91(c) 152.73(c) Last
3 726 335 817 238 1 038 825 1 168 556 841 179 Volume
-2.04% +2.40% +1.09% -1.64% +1.21% Change
More quotes
Financials (USD)
Sales 2021 236 B - -
Net income 2021 1 870 M - -
Net Debt 2021 2 045 M - -
P/E ratio 2021 13,2x
Yield 2021 1,12%
Sales 2022 247 B - -
Net income 2022 2 218 M - -
Net Debt 2022 2 255 M - -
P/E ratio 2022 10,8x
Yield 2022 1,17%
Capitalization 24 760 M 24 760 M -
EV / Sales 2021 0,11x
EV / Sales 2022 0,11x
Nbr of Employees 70 000
Free-Float 59,5%
More Financials
Company
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows: - distribution of pharmaceutical products (91%); - distribution of medical and surgical products (3.5%); - supply of technological services (5.5%). McKesson Corporation also develops a software sales activity. The United States... 
More about the company
Surperformance© ratings of McKesson Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on MCKESSON CORPORATION
07/01MCKESSON : Changes Business-Unit Structure
DJ
07/01MCKESSON CORP : Regulation FD Disclosure, Financial Statements and Exhibits (for..
AQ
07/01MCKESSON : Realigns Organizational Structure to Better Serve Customers and Patie..
BU
06/30KARYOPHARM THERAPEUTICS : XPOVIO, FDA Approved for Treatment of Relapsed or Refr..
AQ
06/29MCKESSON : XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refract..
PU
06/19MCKESSON : Partners with Walmart to Deliver nearly 10 million Critical Medical G..
PU
06/05MCKESSON : Appoints Tom Rodgers to Executive Vice President and Chief Strategy a..
AQ
06/04MCKESSON : Appoints Tom Rodgers to Executive Vice President & Chief Strategy and..
BU
06/03ELI LILLY AND : RETEVMO, FDA-Approved for Treatment of RET-driven Lung and Thyro..
AQ
06/02MCKESSON : RETEVMO (selpercatinib), FDA-Approved for Treatment of RET-driven Lun..
PU
05/29MCKESSON CORPORATION : Ex-dividend day for
FA
05/28MCKESSON : Investigators from US Oncology Research and McKesson Present Data Hig..
PU
05/28INCYTE : Pemazyre Available Exclusively at Biologics by McKesson
AQ
05/27MCKESSON : Pemazyre (pemigatinib) Available Exclusively at Biologics by McKesson
PU
05/22MCKESSON : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
More news
News in other languages on MCKESSON CORPORATION
07/01MCKESSON : Changes Business-Unit Structure
07/01MCKESSON CORP : Regulation FD Disclosure, Financial Statements and Exhibits (for..
07/01MCKESSON : Realigns Organizational Structure to Better Serve Customers and Patie..
06/30KARYOPHARM THERAPEUTICS : XPOVIO, FDA Approved for Treatment of Relapsed or Refr..
06/29MCKESSON : XPOVIO (selinexor), FDA Approved for Treatment of Relapsed or Refract..
More news
Analyst Recommendations on MCKESSON CORPORATION
More recommendations
Chart MCKESSON CORPORATION
Duration : Period :
McKesson Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MCKESSON CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 171,18 $
Last Close Price 152,73 $
Spread / Highest target 27,0%
Spread / Average Target 12,1%
Spread / Lowest Target -3,75%
EPS Revisions
Managers
NameTitle
Brian Scott Tyler Chief Executive Officer & Director
Edward A. Mueller Chairman
Britt Vitalone Chief Financial Officer & Executive Vice President
Nancy Flores EVP, Chief Technology & Information Officer
M. Christine Jacobs Independent Director
Sector and Competitors